Immunai joins 10x Genomics program to boost drug development
Together, the two companies say can give drugmakers a better view at the cellular level of how a patient’s immune system is responding to a cerain therapy.
Together, the two companies say can give drugmakers a better view at the cellular level of how a patient’s immune system is responding to a cerain therapy.
The company, led by an ex-Palantir engineer and a former Harvard postdoctoral researcher, has developed machine learning algorithms to identify nuances in cells, mechanisms of action and biomarkers that could aid immunotherapy and cell therapy development.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.